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        Sepsis is a life-threatening condition that de-
mands treatment within few hours upon clinical 
manifestation (  1, 2  ). Gram-negative and -posi-
tive bacterial infections are the major causes 
of sepsis, which is characterized by extension of 
local infection to the systemic level (  3  –  5  ). Typical 
early fi  ndings include high serum concentrations 
of cytokines such as TNF-    . The early phase of 
sepsis is followed by endocrine and cardiovascular 
dysregulation, often triggering fatal septic shock. 
Evidence of a link between the initial immune 
hyperactivation and a later immunoparalysis con-
tributing to sepsis mortality may emphasize a 
rationale for timely and transient therapeutic 
immunosuppression (  5  ). 
  Binding of pathogen-associated molecular 
patterns (PAMPs), such as envelope constituents 
or nucleic acids, to pattern recognition receptors 
(PRRs) induces infl  ammation upon infection. 
PRRs include Toll-like receptors (TLRs), which 
carry N-terminal leucine-rich repeat (LRR)  –
  rich domains that interact with PAMPs. Ligand 
binding to the ectodomains induces TLR dimer-
ization via the adjacent transmembrane domains. 
C-terminal intracellular domains recruit the 
cytoplasmic adaptor molecules MyD88 and/or 
TRIF/TICAM-1 to initiate intracellular signal 
transduction via specifi  c pathways such as those 
involving NF-    B (  6, 7  ). The immune-stimula-
tory activity of the Gram-negative bacterial outer 
membrane glycolipid LPS depends on binding to 
LPS-binding protein (LBP) and CD14. These 
CORRESPONDENCE  
  Carsten J. Kirschning: 
 carsten.kirschning@lrz.tum.de
  S. Spiller and G. Elson contributed equally to this paper. 
      The online version of this article contains supplemental material.   
  TLR4-induced IFN-     production increases 
TLR2 sensitivity and drives Gram-negative 
sepsis in mice 
    Stephan     Spiller  ,    1       Greg     Elson  ,    2       Ruth     Ferstl  ,    1       Stefan     Dreher  ,    1     
  Thomas     Mueller  ,    1       Marina     Freudenberg  ,    3       Bruno     Daubeuf  ,    2     
  Hermann     Wagner  ,    1     and   Carsten J.     Kirschning      1     
  1  Institute of Medical Microbiology, Immunology, and Hygiene, Technische Universit  ä  t M  ü  nchen, 81675 Munich, Germany 
  2  Novimmune S.A., 1228 Plan-Les-Ouates, Switzerland 
  3  Max Planck Institute of Immunobiology, 79108 Freiburg, Germany     
  Gram-negative bacterial infection is a major cause of sepsis and septic shock. An important 
inducer of infl  ammation underlying both syndromes is the cellular recognition of bacterial 
products through pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). 
We identifi  ed a novel antagonistic mAb (named 1A6) that recognizes the extracellular 
portion of the TLR4  –  MD-2 complex. If applied to mice before infection with clinical iso-
lates of   Salmonella enterica   or   Escherichia coli   and subsequent antibiotic therapy, 1A6 
prevented otherwise fatal shock, whereas application of 1A6 after infection was ineffec-
tive. In contrast, coapplication of 1A6 and an anti-TLR2 mAb up to 4 h after infection with 
Gram-negative bacteria, in combination with the start of antibiotic therapy (mimicking 
clinical conditions), provided robust protection. Consistent with our fi  ndings in mice, dual 
blockade of TLR2 and TLR4 inhibited TNF-     release from human peripheral blood mono-
nuclear cells upon Gram-negative bacterial infection/antibiotic therapy. Both murine 
splenocytes and human PBMCs released IFN-     in a TLR4-dependent manner, leading to 
enhanced surface TLR2 expression and sensitivity for TLR2 ligands. Our results implicate 
TLR2 as an important, TLR4-driven sensor of Gram-negative bacterial infection and provide 
a rationale for blockade of both TLRs, in addition to antibiotic therapy for the treatment of 
Gram-negative bacterial infection. 
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mAb (T2.5) application to inhibit surface TLR2-driven fatal 
shock upon challenge with the Gram-positive bacterium 
  Bacillus subtilis   has been surprising (  12, 19  ). To extend the con-
cept of sole TLR2 blockade and to translate it to an experi-
mental setting mimicking sepsis upon bacterial infection, we 
fi  rst identifi  ed a novel mAb (1A6). 1A6 bound the murine 
TLR4  –  MD-2 complex in a dose-dependent fashion, as well as 
a human (h)TLR4  –  mMD-2 complex (Fig. S1, A  –  C, available 
at http://www.jem.org/cgi/content/full/jem.20071990/DC1). 
Fluorescent staining of WT, but not   TLR4      /       , macrophages 
using 1A6 and subsequent fl  ow cytometry or microscopy 
confi  rmed primarily intracellular TLR4 localization (Fig. S1 D 
and   Fig. 2 A  ).   Co-precipitation of mTLR4 and mMD-2 
from cells overexpressing both proteins (  Fig. 2 B  ) indicated 
the specifi  city of 1A6 for an epitope formed by both chains 
of the murine TLR4  –  MD-2 complex together. Binding of 
1A6 to TLR4  –  MD-2, but not to TLR2, resulted in TLR4 
neutralization and contrasted with the inverse features of 
T2.5 (  Fig. 2, C and D  ; Fig. S2 A). Furthermore, preapplication 
of 1A6 reduced phosphorylation of the mitogen-activated 
protein kinase p38 upon   E  .   coli   infection highly eff  ectively, 
whereas blockade of TLR2 on RAW264.7 macrophages that 
constitutively express TLR2 at a high level was less eff  ective 
(Fig. S2 B and not depicted). Co-application of 1A6 and T2.5, 
but not single mAb application, inhibited TNF-     release from 
proteins deliver LPS to the complex formed by TLR4 and 
MD-2 (  8, 9  ). N-terminally oligo-acylated proteins, produced 
by most if not all bacteria, are PAMPs that activate TLR2  –
  TLR1 or TLR2  –  TLR6 complexes (  7, 10  ). Previous reports 
have shown the relative importance of TLR2 and TLR4 as 
sensors of Gram-negative and -positive bacteria, but have 
indicated involvement of additional PRRs (  11, 12  ). 
  Existing strategies for the prevention of Gram-negative 
bacterial septic shock target infl  ammatory mediators or specifi  c 
PRRs such as CD14. Antagonistic anti  –  rabbit CD14 antibody-
dependent blockade of CD14 has been shown to prevent 
pathology such as organ injury by repetitive LPS challenge 
when applied, even after the initial LPS administration (  13  ). 
Eff  orts to inhibit LPS-induced TLR4 activation include appli-
cation of LBP, antagonistic lipid A, or antagonistic anti  –  murine 
(m)TLR4 mAbs (  14  –  16  ). 
  In this study, we examined the host response to infection 
with clinical isolates of   Escherichia coli   or   Salmonella enterica  . 
Specifi  cally, we investigated whether blockade of TLR4 and/
or TLR2 on murine or human immune cells inhibits cyto-
kine release. In addition, we studied the eff  ect of antibiotic 
therapy paired with such blockade during Gram-negative bac-
terial infection of mice to protect against the Jarisch-Herx-
heimer reaction, which is induced in vivo when PAMPs are 
released rapidly from bacteria exposed to antibiotics (  17  ). 
Results of either single or dual TLR blockade before or upon 
acute Gram-negative bacterial infection showed a central role 
of both TLR4 and TLR2 in sensing of Gram-negative bacte-
rial challenge in vivo, a TLR4  –  TLR2 interrelation, and the 
capacity to protect from shock upon subsequent or synchro-
nous antibiotic therapy. 
    RESULTS AND DISCUSSION   
  Investigating the involvement of TLR2 in addition to TLR4, 
we applied experimental models of Gram-negative bacterial 
infection and subsequent antibiotic therapy both in vitro and 
in vivo (  18  ). We observed TLR2/4-independent activity of 
primary macrophages upon high-dose infection and subse-
quent antibiotic therapy affi   rming the involvement of further 
PRRs (such as TLR9 binding bacterial DNA) (  6  ) in the rec-
ognition of Gram-negative bacteria. However, at lower in-
fection doses,   TLR2      /     /TLR4      /        macrophages were barely 
responsive. Substantial   TLR4      /        macrophage activity upon 
Gram-negative bacterial challenge thus implied a contribut-
ing TLR2 activity (  Fig. 1 A  ).   Next, we infected mice with 
clinical isolates of Gram-negative bacteria. After 1 h, infec-
tion was terminated by antibiotic therapy, which was eff  ec-
tive as indicated not only by the sterility of blood cultures 18 h 
after infection (not depicted) but also by the survival of all 
  TLR2      /       /  TLR4      /        mice (  Fig. 1, B and C  ). As opposed to 
resistance of   TLR2      /       /  TLR4      /        mice,   >  50% of mice lacking 
expression of TLR2 or TLR4 and all WT mice succumbed 
to fatal shock upon   S  .   enterica   and   E  .   coli   infection (followed 
by antibiotic therapy;   Fig. 1, B and C  ). 
  In the face of predominant intracellular TLR2 localiza-
tion in primary immune cells, the eff  ectiveness of anti-TLR2 
    Figure 1.         Impaired responsiveness to Gram-negative bacterial in-
fection followed by antibiotic therapy in the absence of TLR2/TLR4 
expression.   (A – C)  Wild-type  (white  bars,      ),   TLR2    /      (light gray bars,     ), 
  TLR4    /      (dark gray bars,      ), and   TLR2    /    / TLR4    /      (black bars,      ; A) macro-
phages or mice (B and C) were infected with   S .   enterica   (A and B) or  
E .   coli   (A and C) and subjected to antibiotic therapy after 1 h (A  –  C). 
(A) Cell culture supernatants were analyzed for TNF-     content by ELISA 
16 h after challenge or infection as indicated (Pam  3 CSK 4 ,  tripalmitoylated 
hexapeptide; ND, not detected). (B and C) Mice were infected with 10  9  
CFU   S. enterica   ( ent  .) or 5   ×   10  9   CFU   E. coli  . *, P   <   0.003; **, P   <   0.052; 
P values result from comparison to results of respective   TLR2    /    / TLR4    /     
group analysis;   n   = 5 for each experimental group.     JEM VOL. 205, August 4, 2008  1749
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was applied 4 h after LPS injection, a fully protective 1A6 dose 
was 30 mg/kg body weight (Fig. S3 C). Mice were com-
pletely protected from high-dose LPS shock if 1A6 was ap-
plied within a time window of 5 h before challenge and 4 h 
after challenge (Fig. S3, D and E). The diff  erent requirements 
in respect to 1A6 doses might depend on specifi  c demands 
for celerity of TLR4 blockade (Fig. S3, B and C). The pro-
tective eff  ect of systemic 1A6 administration, however, was 
not caused by induction of TLR4  +   cell-specifi  c depletory ac-
tivity, and TLR4  –  MD-2  –  bound 1A6 persisted on the surface 
of macrophages in vitro for at least 4 h (Fig. S4, A  –  C), which 
indicated a slow TLR4  –  MD-2  –  1A6 complex uptake. Based 
on the results of our KO mice and murine macrophage ana-
lyses (  Fig. 1  ), we evaluated dual TLR blockade in respect to 
its protective potential. To this we applied both mAbs sys-
temically before challenge with antibiotic-treated   E  .   coli  . 
Amounts of serum-borne TNF-    , IL-6, and IL-10 were 
equally low in   TLR2      /       /  TLR4      /        mice and 1A6/T2.5-treated 
mice when compared with control mice (  Fig. 3, A  –  C  ).   No-
tably, upon low-dose   S  .   enterica   infection, dual TLR block-
ade in the absence of antibiotic therapy increased bacterial 
loads in diff  erent compartments 24 h after infection to a sig-
nifi  cant degree (  Fig. 3 D  ). Failure to apply antibiotic therapy 
upon acute infection with   S  .   enterica   consequently acceler-
ated pathogenesis within the fi  rst 12 h, as indicated by in-
creased fatality of mice in which dual TLR blockade was 
performed (  Fig. 3 E  ). 
  Surprisingly, prophylactic pretreatment with 1A6 alone, 
but not T2.5 alone, protected WT mice from otherwise 
lethal   E  .   coli   infection/antibiotic therapy (  Fig. 3 F   and not 
depicted). Accordingly, early TLR4 blockade in otherwise 
untreated experimental peritonitis has been protective (  16  ). 
Our fi  ndings on the necessity of concordant dual TLR block-
ade (  Fig. 2 E  ), however, somehow opposed exclusiveness of 
TLR4 involvement; possibly caused by the high TLR2 ex-
pression level in RAW264.7 macrophages used in our initial 
experiments here, which is not apparent in primary macro-
phages (  19  ). That   TLR4      /        mice lacked signifi  cant resistance to 
Gram-negative bacterial challenge (  Fig. 1 C  ) could not be 
explained by a compensatory hyperactivity of TLR2 in  TLR4      /        
mice, because average serum TNF-     concentrations in WT 
and   TLR4      /        mice upon challenge with bacterial lipopep-
tide analogue for 90 min (  n   = 14 for each of the two geno-
types) did not diff  er signifi  cantly (not depicted). Instead, a 
systemically operative TLR4  –  TLR2 interrelation, which is 
outlined in the following paragraphs, provides a possible ex-
planation for the eff  ectiveness of TLR4 preblockade. 
  In modeling treatment of an established Gram-negative 
bacterial sepsis, we fi  rst infected mice with   E  .   coli   or   S  .   enterica  . 
After 1 h, an initial antibiotics administration was performed 
that was accompanied by application of either one of the two 
mAbs or both mAbs together. In accordance with the results 
of our initial experiments, neither of the two mAbs alone 
conferred protection (  Fig. 3, G and H  ). Notably, dual mAb 
application resulted in complete protection against infec-
tion/antibiotics treatment  –  induced shock (  Fig. 3, G and H  ). 
murine macrophages upon   S  .   enterica   or   E  .   coli   infection fol-
lowed by antibiotic therapy (  Fig. 2 E  ). 
  The inhibitory eff  ect of TLR4 blockade during systemic 
LPS challenge depended on both the LPS dose and the 1A6 
dose (Fig. S3, A and B, available at http://www.jem.org/
cgi/content/full/jem.20071990/DC1). For example, if 1A6 
    Figure 2.         mTLR4  –  MD-2 specifi  city of 1A6 and effective TLR4 and 
TLR2 blockade on murine macrophages infected with Gram-nega-
tive bacteria.   (A) Macrophages incubated with anti-TLR4 mAb (1A6) 
shown by Nomarski differential interference contrast microscopy (DIC), 
fl  uorescence recording (middle), and superimposition of both recordings 
(right). Bar, 10   μ  m. (B) Lysates of HEK293 cells that overexpressed murine 
TLR4 and MD-2 were subjected to immunoprecipitation (IP;    ,  anti) 
and analyzed using flag-specific antiserum (lys., total lysates). 
(C and D) HEK293 cells overexpressing mTLR4  –  MD-2 transiently or RAW264.7 
macrophages, respectively, were challenged as indicated upon preincuba-
tion with anti-TLR2 mAb (T2.5), 1A6, or isotype control (i.c.) for 30 min. 
HEK293 cells were lysed 16 h after challenge and assayed for NF-   B –
  driven relative (Rel.) luciferase activity (C), whereas RAW264.7 macro-
phage supernatants were sampled 16 h after challenge (Pam  3 CSK 4 , 
tripalmitoylated hexapeptide) and analyzed by ELISA (D). *, P   <   0.003. 
(E) RAW264.7 macrophages were infected 30 min after incubation with 
1A6 (     ), T2.5 (     ), 1A6 and T2.5 (     ), or isotype control (     ) mAb. Antibiotic 
therapy started 1 h after infection, and supernatants were analyzed by 
ELISA 6 h after infection. Results illustrated represent similar results 
(A, B, and E) or summarize the results (C, D) of at least three indepen-
dent experiments.   1750 GRADED TLR2/TLR4 ACTIVITY IN GRAM-NEGATIVE BACTERIAL INFECTION   | Spiller et al. 
Dual TLR blockade was protective, even if performed in 
synchrony with the start of antibiotic therapy 4 h after infec-
tion (  Fig. 3, I and J  ), even though mice already displayed 
symptoms of severe illness 3 h after infection. The 4-h time 
window of eff  ective treatment is consistent with specifi  c mAb-
mediated protection upon single TLR-specifi  c challenge 
(Fig. S3 E) (  19  ). Our fi  ndings suggest eff  ectiveness of TLR2/
TLR4 blockade in the advanced phase of sepsis pathogenesis 
in which infection becomes clinically manifest, and therefore 
antibiotics are applied. 
  Infection with   E  .   coli   is among the most important causes of 
sepsis (  4  ), which might depend on   E  .   coli   access to the blood-
stream by mechanisms such as trauma. In contrast, salmonellae 
cause enteric disease because of their capacity to traverse epi-
thelial cells lining the intestine or upon breaching tight junc-
tions between them (  20  ). However, only upon infection with 
  S  .   enterica   alone for longer time periods (  Fig. 3, D and E  ), or 
if antibiotic therapy was delayed for 4 h (  Fig. 3 J  ), might epi-
thelial breakage or intracellular inhabitation have contributed 
to evasion from host surveillance, and thus to the increase of 
bacterial load. Indeed, infection with   S  .   enterica   was more 
pathogenic than infection with   E  .   coli   as judged from the ne-
cessity for application of   S  .   enterica   doses that were reduced by 
80% as compared with   E  .   coli   doses to induce similar hyper-
infl  ammation, despite antibiotic therapy. 
  We speculated that the startling protection by TLR4 
blockade before infection, but not after infection (  Fig. 3, 
F and G  ), might indicate a TLR2 trigger function of TLR4 
(  21  ). To evaluate this hypothesis, we challenged mice with 
TLR2 and TLR4 ligands consecutively, at a low dose. Serum 
TNF-     concentrations peaked at 90 min and were reduced 
to background levels 180 min after single challenge of each 
TLR (  Fig. 4 A   and not depicted).   Consistently, sequential (3-h 
interval) TLR4  –  TLR2 activation caused the strongest serum 
TNF-     accumulation after 4.5 h, as compared with single 
TLR2, TLR2  –  TLR4, TLR2  –  TLR2, or even single TLR4 
or TLR4  –  TLR4 activation (  Fig. 4 A  ). This fi  nding was par-
alleled by the persistence of an increased TNF-     level 180 min 
after the second challenge (6 h upon fi  rst challenge) and a fatal 
outcome upon consecutive TLR4  –  TLR2 challenge specifi  cally 
(not depicted). Thus, enhanced TLR2 sensitivity rather than 
tolerance was operative upon TLR4 activation. 
  We reasoned that IFN-     might mediate the TLR4-de-
pendent eff  ect described above, because impairment of IFN-     
function has been reported to attenuate Gram-negative bac-
terial challenge  –  induced pathology (  22  ), and because of the 
protective eff  ect of prophylactic TLR4 blockade (  Fig. 3 F  ). 
Accordingly, Gram-negative bacterial infection caused accu-
mulation of substantial amounts of IFN-     within a 3-h time 
frame in the sera of WT mice in a TLR4-dependent man-
ner (  Fig. 4 B  ). Splenic NK cells (CD3  -  NK1.1  +  ), NKT cells 
(CD3  +  NK1.1  +  ), and a low but substantial frequency of T cells 
    Figure 3.         Systemic blockade of both TLR4 and TLR2 upon   S  .   en-
terica   or   E  .   coli   challenge inhibits cytokine release, enhances pa-
thology if an infection is not followed by antibiotic therapy, and 
protects from septic shock if synchronized with the start of antibi-
otic therapy.   (A  –  C) Mice received 1A6 and T2.5 mAb (     ;   n   = 6) or isotype 
control mAb (    ;   n   = 6) 1 h before i.p. challenge with 5   ×   10  7   CFU   E .   coli  
that had been pretreated with antibiotics in vitro immediately before 
injection (    ,   TLR2    /    / TLR4    /      mice, used as positive control;   n   =  3). 
Serum samples drawn as indicated were subjected to ELISA. Each experi-
mental group was analyzed in the course of three individual experiments. 
(D) Wild-type mice received mAbs (i.c., isotype control; T2.5, anti-TLR2; 
1A6, anti-TLR4) 1 h before infection with 10  6   CFU   S .   enterica   ( ent  .) by i.p. 
injection. 24 h later, mice were killed and bacterial loads of compart-
ments indicated were determined (  n   = 6 for each experimental group). 
(E  –  J) Wild-type mice received mAb (     , isotype control;     ,  1A6;      , T2.5; 
     , 1A6 and T2.5; *, P   <   0.004 for comparison to specifi  c dual TLR blockade 
groups): 1 h before infection with 10  8   CFU   S .   enterica   to be left untreated 
thereafter (E;   n   = 7 per group split for three independent experiments), 
1 h before infection with 5   ×   10  9   CFU   E. coli   and 2 h before antibiotic 
therapy (F;   n   = 5 per group split for two independent experiments), at the 
start of antibiotic therapy 1 h after infection with 5   ×   10  9   CFU   E .   coli   or 
10  9   CFU   S .   enterica   (G and H; two individual experiments with   n   = 5 per 
group), or (results of three individual experiments) at the start of antibi-
otic therapy 4 h after infection with 5   ×   10  8   CFU   E .   coli   ( n   = 9 for     , 
  n   = 10 for      ) or 10  8   CFU   S .   enterica   ( n   = 10 for both experimental groups; 
I and J).     
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from WT mice were found to already express IFN-     2 h 
after systemic infection with   S  .   enterica  , whereas the number 
of IFN-     producers was substantially lower in spleens from 
  TLR4      /        mice ( Fig. 4, C and D , and Fig. S5, A and B, available 
at http://www.jem.org/cgi/content/full/jem.20071990/DC1). 
Activated TLR4 induces proinfl  ammatory cytokine production 
by recruitment of MyD88, whereas it mediates late NF-    B ac-
tivation and type I IFN- synthesis through TRIF/TICAM-1 
(  7  ). Notably, TLR4-driven IFN-     release from splenocytes was 
MyD88-dependent, but did not depend on TRIF/TICAM-1 
(  Fig. 4 E  ). In addition, IFN-     priming for 3 h increased cellu-
lar responsiveness to TLR2 ligand challenge (  Fig. 4 F  ) and cell 
surface TLR2 expression on C57BL/6 or 129Sv WT CD11b  +   
cells was increased 3 h after   S  .   enterica   infection, whereas an 
up-regulation of TLR2 was undetectable in infected   TLR4      /        
and IFN-    R  –  defi  cient (  IFN-    R      /       ) mice (  Fig. 4 G   and 
not depicted). 
  Our fi   ndings are consistent with both TLR2 mRNA 
augmentation and cell surface TLR2 increase upon LPS chal-
lenge in humans (  23, 24  ). They also correspond with the en-
hanced cell surface TLR2 expression in farmers  ’   children as 
compared with controls, a fi  nding that has been linked to ex-
posure to higher amounts of LPS (  25  ). The translation poten-
tial of our preclinical data is further supported by the eff  ective 
inhibition of TNF-     release from hPBMCs upon infection 
with each of the two Gram-negative bacteria through mAb-
mediated TLR2/TLR4 blockade (  Fig. 5 A  ).   TLR4, but not 
TLR2, blockade on hPBMCs inhibited rapid IFN-     release 
upon   E  .   coli   infection. Accordingly, although LPS challenge 
induced IFN-     release from hPBMCs, acylated hexapeptide 
did not (  Fig. 5 B  ). Furthermore, IFN-     challenge enhanced 
TLR2-specifi  c hPBMC activation if applied 3 h before TLR2 
challenge (  Fig. 5 C  ). 
  Antagonism of primary infl  ammatory mediators, such as of 
TNF-    , IL-6, or IL-1    , is being evaluated. Blockades of dif-
ferent cytokines are currently being used as therapies of chronic 
infl  ammatory diseases. Yet, they have proved less successful 
for the treatment of acute infection, possibly caused by redun-
dant activities via untargeted cytokines. Targeting late medi-
ators of sepsis has proved successful in experimental models of 
sepsis, as demonstrated by antagonism of macrophage migra-
tion inhibitory factor or high-mobility group box 1 protein 
(  26, 27  ). Using an experimental model of hyperinfl  ammation 
induced by Gram-negative bacterial infection coupled to anti-
biotic therapy, we show a 4-h window of opportunity for 
protective TLR2/TLR4 blockade, contrasting the hypothesis 
of immediate early TLR activation as a point of no return. Our 
data also imply a time-dependent accumulation of infl  ammatory 
    Figure 4.         Timely graduated TLR4  –  TLR2 activation induces maxi-
mal cell activation and correlates with TLR4- and MyD88-
dependent release of IFN-     by NK and NKT cells to enhance 
TLR2-specifi  c sensitivity and surface TLR2 expression upon Gram-
negative bacterial infection.   (A) Mice were challenged by i.p. injection 
of 50   μ  g LPS or 50   μ  g dipalmitoylated hexapeptide (P  2  C), or they were left 
untreated (none;   n   = 6 per experimental group). After a second challenge 
(or none) at 180 min, serum was drawn at 270 min and analyzed by ELISA. 
*, P   <   0.004. ND, not detected. (B) Mice were infected with 5   ×   10  8   CFU   
E. coli   or 10  8   CFU   S. enterica   ( ent.  ) for 3 h, after which serum was sampled 
and analyzed by ELISA. *, P   <   0.004 (inf., infected; WT,   n   = 4;   n   = 3 for 
each   TLR4    /      group). (C and D) Murine splenocytes were prepared 2 h 
after systemic infection with 10  8   CFU   S .   enterica  . Viable CD3        and  CD3 +  
fractions of splenocytes were analyzed for NK 1.1 (NK and NKT, respec-
tively) and intracellular IFN-     expression. (E) Splenocytes from wild-type 
(     , white bar),   TRIF    /      (    , black bar),   MyD88    /      (    , light gray bar), and 
  TRIF    /    /MyD88     /      (    , dark gray bar) mice were challenged for 24 h 
ex vivo upon which supernatants were analyzed by ELISA (3.5   μ  g/ml    CD3 
as control, represents two independent experiments). (F) Primary macro-
phages were IFN-     primed for 3 h or left untreated (    ). Cells were 
washed twice and challenged with 1 ng/ml lipopeptide (Pam  3 CSK 4 ,  white 
bars), 10 ng/ml (gray bars), or 100 ng/ml (black bars) for an additional 6 h 
and analyzed by ELISA. *, P   <   0.006 (represents three independent experi-
ments). (G) Splenocytes were isolated 3 h after   S .   enterica   infection  of 
mice (10  8   CFU) with indicated genotypes and the CD11b  +   fraction  was 
analyzed for surface TLR2 expression (representative of at least three 
independent  experiments).   
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tion also reduces sepsis-related apoptosis and/or immuno-
paralysis (  5  ), as deduced from TLR2/TLR4 blockade  –  dependent 
IL-10 reduction (  Fig. 3 C  ). In conclusion (Fig. S6, available 
at http://www.jem.org/cgi/content/full/jem.20071990/DC1), 
our data implicate IFN-     as a TLR4  –  MyD88  –  driven inducer 
of up-regulation of surface TLR2 expression and toxemia-
related TLR2 sensitivity. Our preclinical results suggest that 
blockade of both TLR2 and the TLR4  –  MD-2 complex is a 
therapeutic approach to eff  ectively inhibit Gram-negative 
bacterial infection  –  induced immunopathology during anti-
biotic therapy. 
    MATERIALS AND METHODS   
  Reagents, bacteria, cells, cell lines, mice, and TLR2/TLR4 blockade.   
  LPS from   S  .   enterica   serovar Minnesota strain R595, polyinosinic-polycyti-
dylic acid (poly-I:C; both from Sigma-Aldrich) and di- or tripalmitoyl-
cysteinyl-seryl-(lysyl)3-lysine (EMC microcollections) were applied at 
100 ng/ml unless otherwise indicated. Thiolated DNA (#1668) was applied 
at 2   μ  M (TIB MOLBIOL) and anti  –  mouse-CD3     was applied at 1   μ  g/ml 
(145-2C11; BD Biosciences), or IFN-     (PeproTech) at 20 ng/ml. As the 
isotype-matched control for 1A6 (rat IgG2b) and T2.5 (mouse IgG1, mTLR2, 
and hTLR2-specifi  c; HBT), equal amounts of unspecifi  c 11G8 (rat IgG2b) 
and mTLR2-specifi  c mouse mT2.13 (neutral, mouse IgG1), respectively, 
were blended (  12, 19  ). Anti-hTLR4 mAb (15C1; isotype control mT2.13) 
has been previously described (  12  ). mAbs were applied at 25   μ  g/ml in vitro 
or 30 mg/kg in vivo. Clinical isolate clones of   S. enterica   subspecies enterica 
serovar enteritidis and   E. coli   were cultured (16 h, 37  °  C) in standard media. 
Bacteria were used for infections both in vivo and in vitro. The bacterial 
dosage applied in vivo corresponded to a minimal dose that was lethal, de-
spite antibiotic therapy. For antibiotic therapy in vitro, antibiotics (100   μ  g/ml 
ampicillin, 10   μ  g/ml ofl  oxacin; Sigma-Aldrich) were applied once 1 h after 
infection. Upon systemic infection, 68 mg/kg ampicillin and 2.8 mg/kg 
ofl  oxacin were applied i.p. at the antibiotic therapy starting time points 
indicated, and an additional 3 times (hourly) without mAbs. For deter-
mination of bacterial loads upon infection of mice and subsequent cervi-
cal dislocation, aliquots of serial dilutions of blood and organ suspensions 
were plated. 
  Immunization and mAb identifi  cation.     Male Wistar rats were subcu-
taneously immunized 3 times within 6 wk with 10  6   CHO/mTLR4  –  MD-
2 cells suspended in monophosphoryl-lipid A/trehalose dicorynomycolate 
adjuvant (RIBI; Sigma-Aldrich). Immunized rats were challenged sub-
cutaneously with 10   μ  g recombinant mTLR4-mMD-2 (mTLR4 ecto-
domain aa 1  –  629 fused to mMD-2 aa 19  –  170 via a peptide linker in RIBI). 
Lymph node cells were fused with Sp2/0 myeloma cells after 3 d (  12  ). 
Hybridoma supernatants were screened for binding to mTLR4  –  MD-2 by 
fl  ow cytometry. 
  Mice.       TLR2      /        (provided by Amgen, South San Francisco, CA) and 
  TLR4      /        (provided by K. Hoshino and S. Akira, Osaka University, Osaka, 
Japan) mice were backcrossed toward the C57BL/6 background (WT) nine 
times and intercrossed (  TLR2      /     /TLR4      /       ) (  27, 28  ).   MyD88      /        and   TRIF      /        
mice were backcrossed toward the C57BL/6 background (WT) six times 
and intercrossed ( MyD88      /     /TRIF       /       ; provided by T. Kawaii, K. Hoshino, 
and S. Akira, Osaka University, Osaka, Japan) (  29  ).   IFN-    R      /        mice were 
on 129Sv background (  30  ). All animal experiments were approved by the 
Government of Upper Bavaria, Germany. 
  Flow cytometry.     CD3 (FITC), IFN-     (APC), CD11b (APC), NK1.1 
(PE), CD8 (Alexa405), CD4 (PE; all from BD Bioscience), fl  ag-tag (M2; 
Sigma-Aldrich), MTS510 (rat anti  –  mouse TLR4; Abcam), and/or TLR2 
(FITC, mT2.7, or T2.5; HBT) for analysis by fl  ow cytometry. For detection 
of unlabeled rat 1A6 or mouse T2.5, mouse anti  –  rat Fc     or rat anti  –  mouse 
TLR signals encompassing one signal that   “  switches on  ”   second 
line TLR2-specifi  c sensitivity, which might depend on fi  rst 
line TLR4 activation upon a Gram-negative bacterial insult. 
Therefore, eff  ective interference with pattern recognition con-
comitant with initiation of antibiotic therapy might be possible 
even in an advanced phase of sepsis pathology after infection. 
It is conceivable that dual TLR antagonism (as demonstrated 
in this study), as well as late mediator blockade and other 
concepts of sepsis pathology inhibition might have to match 
with each other or complement one another to defi  ne the most 
eff  ective therapy. 
  It remains to be shown whether, in addition to averting a 
  “  storm  ”   of cytokines, transient TLR blockade upon infec-
    Figure 5.     Dual TLR blockade inhibits TNF-     release, whereas 
TLR4-specifi  c blockade impedes IFN-     release from hPBMCs upon 
Gram-negative bacterial infection and IFN-     enhances TLR2-spe-
cifi  c, but not TLR4-specifi  c responsiveness of hPBMCs.   (A)  hPBMCs 
were preincubated with mAbs for 30 min (     , 15C1;      , T2.5;     ,  15C1 
and T2.5;      , isotype control), infected with the indicated doses of 
  S. enterica   or   E. coli  , and treated by application of antibiotics after 1 h. 
Supernatant was analyzed 6 h after infection by ELISA. Illustration rep-
resents one out of three equivalent results of three independent experi-
ments. (B) 30 min before infection with 10  5   CFU/ml or 10  6   CFU/ml   E .   coli  
and subsequent antibiotic therapy, hPBMCs were pretreated with mAbs 
(i.c., isotype control). Nonpretreated cells were challenged with 100 ng/ml 
or 1   μ  g/ml LPS or tripalmitoylated hexapeptide (Pam  3 CSK 4 ).  Triangles 
indicate smaller and larger doses. IFN-     in the supernatants was ana-
lyzed 16 h after challenge by ELISA (ND, not detected; illustration repre-
sents summarized results of three independent experiments; *, P = 
0.027). (C) hPBMCs were primed with IFN-     for 3 h (shaded bars) or left 
untreated (open bars). Subsequently, cells were washed twice by cen-
trifugation and challenged with TLR agonists (Pam  3 CSK  4 , lipopeptide) or 
infected with 10  6   CFU/ml   E .   coli   and subjected to antibiotic therapy 
after 1 h. Supernatants sampled 5 h after challenge were analyzed by 
ELISA (summarized result of fi  ve independent experiments; *, P   <   0.02; 
**, P = 0.26).     JEM VOL. 205, August 4, 2008  1753
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